Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 79.00 | |
5 mg | In stock | $ 188.00 | |
10 mg | In stock | $ 279.00 | |
25 mg | In stock | $ 479.00 | |
50 mg | In stock | $ 686.00 | |
100 mg | In stock | $ 997.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 197.00 |
Description | CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells. |
Targets&IC50 | CDK8:14 nM(Ki), GSK-3α:13 nM(ki), GSK-3β:4 nM(ki), PCKθ:109 nM(ki), MV-4-11 cells:0.36 μM(GI50) |
In vitro | CDK8-IN-12 (0.36, 0.72 μM ; 2 h) significantly reduced the phosphorylation of STAT1 serine 727.[1] |
In vivo | CDK8-IN-12 (intravenous administration ; 5 mg/kg in rats ; 2 mg/kg in mice) had a T1/2 of 0.9 h and 0.34 h in rats and mice, respectively.[1] |
Molecular Weight | 381.86 |
Formula | C21H20ClN3O2 |
CAS No. | 2613307-67-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (72.02 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CDK8-IN-12 2613307-67-6 Cell Cycle/Checkpoint PI3K/Akt/mTOR signaling Stem Cells CDK GSK-3 CDK8IN12 inhibitor inhibit